Related references
Note: Only part of the references are listed.Heart Failure With Preserved Ejection Fraction Mechanisms, Clinical Features, and Therapies
Kavita Sharma et al.
CIRCULATION RESEARCH (2014)
Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
P.R.A. Heckman et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3β
Jonathan A. Kirk et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Advances in targeting cyclic nucleotide phosphodiesterases
Donald H. Maurice et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy
Kinya Seo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Nitric Oxide Synthases in Heart Failure
Ricardo Carnicer et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction A Randomized Clinical Trial
Margaret M. Redfield et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
Stephen J. Greene et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction
Loek van Heerebeek et al.
CIRCULATION (2012)
A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In Vivo
Jennifer Davis et al.
DEVELOPMENTAL CELL (2012)
Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders
Patrick R. Verhoest et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection
Rakesh C. Kukreja et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo
Robin J. Kleiman et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Designer natriuretic peptides: a vision for the future of heart failure therapeutics
Rosita Zakeri et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2011)
cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes
Alessandra Stangherlin et al.
CIRCULATION RESEARCH (2011)
Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart
Hideyuki Kinoshita et al.
CIRCULATION RESEARCH (2010)
Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition
Norimichi Koitabashi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart
Bin Zhou et al.
NATURE (2008)
Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors
Lydia W. M. Nausch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Compartmentalization of cardiac β-adrenergic inotropy modulation by phosphodiesterase type 5
Eiki Takimoto et al.
CIRCULATION (2007)
Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart - Downregulation of natriuretic peptide receptor-A in heart failure
Gurminder Singh et al.
CIRCULATION RESEARCH (2006)
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
LRV Castro et al.
CIRCULATION (2006)
Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability
T Oka et al.
CIRCULATION RESEARCH (2006)
Role of cyclic GMP in gene regulation
RB Pilz et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
E Takimoto et al.
NATURE MEDICINE (2005)
In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: Role of phosphodiesterase type 5 phosphorylation
F Mullershausen et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Share Paper
